Worth Watching Stock for Traders: Biopharmx Corp (NYSE: BPMX)

BioPharmX Corporation (American: BPMX) just recently reports monetary results for the fiscal quarter ended July 31, 2019.

Its current trading capacity is 155701 shares versus to its average trading volume of 394923 shares. BPMX traded as low as $ 0.3 in the past 52 weeks, and shares struck its peak level to $5.

2nd Quarter Financial Results

Cash and money equivalents were $ 3.3 M since July 31, 2019.

Not Including stock-based settlement expense and the effect of modification in reasonable value of warrant liability, non-GAAP net loss for the financial quarter ended July 31, 2019 was $ 2.5 M, or $ 0.20 per share. During the second quarter of the previous financial year, the equivalent non-GAAP net loss was $ 4.0 M, or $ 0.52 per share.

For the second financial quarter ended July 31, 2019, total operating costs were $ 2.7 M, contrast with total business expenses of $ 4.5 M in the previous s 2nd quarter.

Net loss for the financial quarter ended July 31, 2019 was $ 2.6 M, or $ 0.22 per share, contrast with a net loss of $ 4.4 M, or $ 0.58 per share, during the previous financial years second quarter.

.

Looking about the past efficiency history, the company lost at -0.93% in past week and declined with -10.71% in one month. During the past three-month period the stock dropped of -44.11% and reduced at -84.74% in previous six month. During the twelve month it fell at -93.21% and year to date efficiency of -87.70%.

Errol Bradford

Errol Bradford – Healthcare My name is Errol Bradford , I have worked for the stock market industry for 4 years. Healthcare news grasp my attention the most. In early days, I started my journey with an ordinary author. Moving forward with great hard work and passion I achieve a higher position. As I believe in working hard and putting the soul in my work, I have accomplished so much success and place in newsgrowing.com, and now I have confidence in this, that I am the spin of this network. I have a vision of touching the sky. I wish to see this industry on a global scale one day. My other duties are that I am a contributor and an editor of the technology segment. My work is to do a critical analysis of companies and pick out the most significant information for investor network.

Leave a Reply

Your email address will not be published. Required fields are marked *